BACKGROUNDClinicalTier 1

Histatin–Photodynamic Therapy for Polyene-Resistant Biofilms in a 3D Model

SourceJournal of Dental Research (JDR)Tier 1Peer-Reviewed Research

By L.M. Dias, A.C. Pavarina, W.L. Siqueira

Originally at journals.sagepub.com

Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.

Why it matters for dental

Basic-science findings on histatin–photodynamic therapy against mixed Candida–S. mutans biofilms may eventually inform new adjunctive treatments for refractory oral candidiasis, but the work remains preclinical and offers no immediate changes to practice protocols, materials, or billing.

Key points

  • Published in Journal of Dental Research (July 2026, Vol. 105, Issue 8) using a 3-D in-vitro model of polyene-resistant biofilms.
  • Tested Histatin 3 and Histatin 5 peptides combined with photodynamic activation; no human or animal dosing data yet.
  • Potential future relevance for immunocompromised or xerostomic patients with azole/polyene-resistant thrush, but no marketed product or guideline change expected soon.
  • Owners and associates should continue standard antifungals and oral-hygiene measures; monitor peer-reviewed follow-up studies for translational data.

Who should care

SpecialistAssociate

Read the original on Journal of Dental Research (JDR)

Full reporting and any paywall content live on journals.sagepub.com. We summarize and score; we do not republish.

Open original

Related